Research Article
Which Has a Greater Impact on the Recurrence in Young Breast Cancer Patients: Recent Childbirth or Recent Breastfeeding?
| | Parity group (1013) | Nulliparous (N = 96) | PPBC <2 (N = 120) | PPBC 2–5 (N = 209) | PPBC 5–10 (N = 312) | PPBC >10 (N = 276) | |
| | Patients with recurrence, n (%) | | Yes | 18 (18.8) | 33 (27.5) | 34 (16.3) | 48 (15.4) | 33 (12.0) | 0.004 | | No | 78 (81.2) | 87 (72.5) | 175 (83.7) | 264 (84.6) | 243 (88.0) | | Age at diagnosis, mean (SD), y | 30.8 (5.2) | 32.1 (3.8) | 32.9 (4.2) | 35.1 (3.2) | 37.5 (2.2) | 0.000 | | Age at diagnosis, n (%) | | 20–30 | 54 (56.3) | 42 (35.0) | 67 (32.1) | 28 (9.0) | 1 (0.4) | 0.000 | | 31–35 | 17 (17.7) | 52 (43.3) | 83 (39.7) | 131 (42.0) | 52 (18.8) | | 36–42 | 25 (26.0) | 26 (21.7) | 59 (28.2) | 153 (49.0) | 233 (80.8) | | Breastfeeding duration, n (%) | | ≤6 months | — | 60 (50.0) | 86 (41.1) | 128 (41.0) | 98 (35.5) | 0.002 | | 7–12 months | — | 43 (35.8) | 89 (42.6) | 157 (50.3) | 157 (56.9) | | ≥12 months | — | 11 (9.2) | 30 (14.4) | 25 (8.0) | 21 (7.6) | | Missing | — | 6 (5.0) | 4 (1.9) | 2 (0.6) | 0 (0.0) | | Family history, n (%) | | Yes | 6 (6.2) | 10 (8.3) | 17 (8.1) | 18 (5.8) | 24 (8.7) | 0.872 | | Year of diagnosis, n (%) | | 2003–2016 | 44 (45.8) | 58 (48.3) | 111 (53.1) | 151 (48.4) | 159 (57.6) | 0.123 | | 2017–2019 | 52 (54.2) | 62 (51.7) | 98 (46.9) | 161 (51.6) | 117 (42.4) | | | Histological grade n (%) | | I | 2 (2.1) | 0 (0.0) | 2 (1.0) | 5 (1.6) | 2 (0.7) | 0.258 | | II | 33 (34.4) | 31 (25.8) | 64 (30.6) | 114 (36.5) | 97 (35.1) | | III | 33 (34.4) | 57 (47.5) | 104 (49.8) | 131（42.0） | 133 (48.2) | | Missing | 28 (29.2) | 33 (26.7) | 39 (18.7) | 62 (19.9) | 44 (15.9) | | Nodal involvement, n (%) | | N0 | 49 (51.0) | 50 (41.7) | 92 (44.0) | 164 (52.6) | 136 (49.3) | 0.154 | | N1+ | 42 (43.8) | 70 (58.3) | 109 (52.2) | 144 (46.2) | 13 (47.5) | | Missing | 5 (5.2) | 0 (0.0) | 8 (3.8) | 4 (1.3) | 9 (3.3) | | Estrogen status, n (%) | | ER+ | 64 (66.7) | 68 (56.7) | 141 (67.5) | 218 (69.9) | 191 (69.2) | 0.097 | | ER− | 32 (33.3) | 51 (42.5) | 67 (32.1) | 90 (28.8) | 84 (30.4) | | Missing | 0 (0.0) | 1 (0.8) | 1 (0.5) | 4 (1.3) | 1 (0.4) | | Surgery type, n (%) | | Total mastectomy | 52 (54.2) | 88 (73.3) | 152 (71.8) | 219 (70.2) | 192 (69.6) | 0.133 | | Breast-conserving | 35 (36.5) | 29 (24.2) | 56 (26.8) | 85 (27.2) | 84 (30.34) | | Missing | 9 (9.4) | 3 (2.5) | 3 (1.4) | 8 (2.6) | 0 (0.0) | | Chemotherapy, n (%) | | Yes | 92 (95.8) | 117 (97.5) | 204 (97.6) | 294 (94.2) | 265 (96.0) | 0.608 | | No | 2 (2.1) | 3 (2.5) | 4 (1.9) | 12 (3.8) | 11 (4.0) | | Missing | 2 (2.1) | 0 (0.0) | 1 (0.5) | 6 (1.9) | 0 (0.0) | | Radiation therapy, n (%) | | Yes | 68 (70.8) | 80 (66.7) | 144 (68.9) | 204 (65.4) | 189 (68.5) | 0.716 | | No | 23 (24.0) | 37 (30.8) | 61 (29.2) | 100 (32.1) | 82 (29.7) | | Missing | 5 (5.2) | 3 (2.5) | 4 (1.9) | 8 (2.6) | 5 (1.8) | | Endocrine therapy, n (%) | | Yes | 59 (61.5) | 59 (49.2) | 124 (59.3) | 202 (64.7) | 186 (67.4) | 0.010 | | No | 30 (31.2) | 53 (44.2) | 70 (33.5) | 85 (27.2) | 81 (29.3) | | Missing | 7 (7.3) | 8 (6.7) | 15 (7.2) | 25 (8.0) | 9 (3.3) | | Targeted therapy, n (%) | | No | 74 (77.1) | 86 (71.7) | 155 (74.2) | 223 (71.5) | 230 (83.3) | 0.076 | | Single target | 17 (17.7) | 28 (23.3) | 46 (22.0) | 76 (24.4) | 40 (14.5) | | Double targets | 1 (1.0) | 3 (2.5) | 5 (2.4) | 3 (1.0) | 3 (1.1) | | Missing | 4 (4.2) | 3 (2.5) | 3 (1.4) | 10 (3.2) | 3 (1.1) |
|
|
